mianserin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1796 24219-97-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mianserin hydrochloride
  • mianserin
  • mianserine
  • (+/-)-Mianserin
  • mianserine hydrochloride
  • mianserin HCl
  • mianserine HCl
A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
  • Molecular weight: 264.37
  • Formula: C18H20N2
  • CLOGP: 3.76
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -3.06
  • ROTB: 0

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.48 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 21.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1976 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 131.76 27.90 141 5250 211625 46469046
Coma 125.18 27.90 80 5311 58269 46622402
Hyponatraemia 122.68 27.90 98 5293 101234 46579437
Hepatocellular injury 104.41 27.90 56 5335 29466 46651205
Somnolence 98.53 27.90 105 5286 156416 46524255
Cholestasis 89.48 27.90 49 5342 26844 46653827
Fall 81.54 27.90 140 5251 328957 46351714
Drug interaction 74.96 27.90 104 5287 202990 46477681
Bradypnoea 73.60 27.90 23 5368 3016 46677655
Agranulocytosis 69.88 27.90 39 5352 22146 46658525
Poisoning deliberate 68.77 27.90 28 5363 7898 46672773
Bradycardia 65.32 27.90 57 5334 66241 46614430
Altered state of consciousness 62.71 27.90 37 5354 23311 46657360
Camptocormia 61.99 27.90 12 5379 207 46680464
Pleurothotonus 60.62 27.90 16 5375 1149 46679522
Miosis 59.41 27.90 24 5367 6633 46674038
Sedation complication 53.84 27.90 19 5372 3626 46677045
Brain death 50.57 27.90 17 5374 2806 46677865
Thymus disorder 50.45 27.90 10 5381 196 46680475
Blood lactic acid 49.23 27.90 9 5382 112 46680559
Housebound 49.01 27.90 10 5381 228 46680443
Acute kidney injury 48.85 27.90 93 5298 235762 46444909
Extrapyramidal disorder 44.41 27.90 23 5368 11245 46669426
Confusional state 42.00 27.90 70 5321 159822 46520849
Cutaneous lymphoma 40.01 27.90 8 5383 164 46680507
Limbic encephalitis 37.36 27.90 8 5383 232 46680439
Vertigo 36.35 27.90 37 5354 52011 46628660
Behaviour disorder 35.88 27.90 12 5379 1949 46678722
Gamma-glutamyltransferase increased 34.71 27.90 29 5362 31711 46648960
Drug abuse 33.65 27.90 39 5352 63369 46617302
Drug-device interaction 33.50 27.90 6 5385 66 46680605
Disorientation 30.92 27.90 29 5362 36889 46643782
Antipsychotic drug level above therapeutic 30.87 27.90 9 5382 932 46679739
Disturbance in attention 30.77 27.90 27 5364 31533 46649138
Suicide attempt 29.45 27.90 34 5357 55002 46625669
Persecutory delusion 29.11 27.90 11 5380 2544 46678127

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral artery thrombosis 66.90 24.95 15 3676 506 29948281
Poikiloderma 50.87 24.95 10 3681 175 29948612
Somnolence 49.19 24.95 60 3631 96703 29852084
Brain scan abnormal 48.16 24.95 12 3679 641 29948146
Reticulocytosis 45.63 24.95 10 3681 303 29948484
Initial insomnia 43.11 24.95 15 3676 2574 29946213
Agranulocytosis 40.24 24.95 28 3663 21914 29926873
Adenomatous polyposis coli 39.27 24.95 8 3683 169 29948618
Hepatocellular injury 36.50 24.95 28 3663 25443 29923344
Coma 36.38 24.95 34 3657 40415 29908372
Anti-platelet antibody positive 35.73 24.95 8 3683 268 29948519
Coombs direct test positive 35.14 24.95 8 3683 289 29948498
Haptoglobin decreased 34.70 24.95 9 3682 565 29948222
Dry mouth 34.68 24.95 26 3665 22824 29925963
Meningioma 34.57 24.95 11 3680 1432 29947355
Blood glucose fluctuation 34.57 24.95 14 3677 3647 29945140
Respiratory distress 34.13 24.95 30 3661 32942 29915845
Blood bilirubin unconjugated increased 33.11 24.95 9 3682 677 29948110
Areflexia 31.29 24.95 12 3679 2707 29946080
Lichenoid keratosis 30.55 24.95 11 3680 2083 29946704
Cholestasis 28.45 24.95 24 3667 24926 29923861
Ischaemic stroke 28.05 24.95 20 3671 16255 29932532
Confusional state 26.45 24.95 54 3637 134780 29814007
Nightmare 25.93 24.95 17 3674 12059 29936728
Poor quality sleep 25.46 24.95 14 3677 7227 29941560
Skin hypertrophy 25.01 24.95 10 3681 2519 29946268

Pharmacologic Action:

SourceCodeDescription
ATC N06AX03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D018663 Adrenergic Agents
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
CHEBI has role CHEBI:35469 thymoanaleptics
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:35678 histamine agonists
CHEBI has role CHEBI:35717 sedatives
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:76779 prolyl oligopeptidase (ec 3.4.21.26) inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.2 Basic
pKa2 1.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 8.12 WOMBAT-PK IUPHAR
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.17 WOMBAT-PK IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.52 WOMBAT-PK IUPHAR
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 7.50 IUPHAR
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 7.40 IUPHAR
Histamine H2 receptor GPCR Ki 6.00 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.46 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 6.42 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.53 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.64 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel Ki 6.21 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.55 CHEMBL
D(2) dopamine receptor GPCR Ki 5.66 CHEMBL
D(4) dopamine receptor GPCR IC50 5.48 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.26 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 6.39 CHEMBL
5-hydroxytryptamine receptor 1F GPCR Ki 8.06 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 8.42 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 6.99 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 7.53 WOMBAT-PK
Histamine H4 receptor GPCR EC50 6.12 WOMBAT-PK
Histamine H1 receptor GPCR Ki 9.25 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.57 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.06 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.17 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.13 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Kd 7.15 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 8.32 WOMBAT-PK
D(1A) dopamine receptor GPCR Ki 6 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.03 PDSP
Sodium-dependent serotonin transporter Transporter Ki 5.40 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.18 DRUG MATRIX
5-hydroxytryptamine receptor 7 GPCR Ki 7.20 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 5.54 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.96 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR IC50 5.72 CHEMBL
Serotonin 3 receptor (5HT3) Ion channel Ki 6.60 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 10.15 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.21 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 6.24 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.37 CHEMBL
Cerebral cortex alpha adrenergic receptor GPCR IC50 8.22 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 5.33 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.85 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.77 CHEMBL
D(2) dopamine receptor GPCR Ki 6.08 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 7.15 CHEMBL
Transporter Transporter Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 8.85 CHEMBL
G-protein coupled receptor Unclassified IC50 4.14 CHEMBL
D(3) dopamine receptor GPCR Ki 5.82 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.82 CHEMBL
Histamine H1 receptor GPCR Ki 9.07 CHEMBL
5-hydroxytryptamine receptor 1B Unclassified ANTAGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.40 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7 IUPHAR

External reference:

IDSource
D01358 KEGG_DRUG
21535-47-7 SECONDARY_CAS_RN
4027429 VANDF
C0025912 UMLSCUI
CHEBI:51137 CHEBI
CHEMBL6437 ChEMBL_ID
CHEMBL544428 ChEMBL_ID
D008803 MESH_DESCRIPTOR_UI
DB06148 DRUGBANK_ID
135 IUPHAR_LIGAND_ID
2543 INN_ID
250PJI13LM UNII
4184 PUBCHEM_CID
203127 RXNORM
18113 MMSL
004006 NDDF
004007 NDDF
387565003 SNOMEDCT_US
395795008 SNOMEDCT_US
96200003 SNOMEDCT_US

Pharmaceutical products:

None